Several other equities analysts have also recently issued reports on CLIN. Numis Securities upgraded Clinigen Group to a buy rating in a research report on Thursday, May 31st. Berenberg Bank reiterated a buy rating and set a GBX 1,160 ($14.96) price target on shares of Clinigen Group in a research report on Wednesday, May 23rd. Five analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and a consensus price target of GBX 1,260.60 ($16.26).
Shares of Clinigen Group stock opened at GBX 943.39 ($12.17) on Tuesday. Clinigen Group has a 1-year low of GBX 751.50 ($9.69) and a 1-year high of GBX 1,187 ($15.31).
Clinigen Group Company Profile
Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.
Further Reading: Average Daily Trade Volume Explained
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.